Lantern Pharma FY2024 EPS Forecast Lifted by Zacks Small Cap

Lantern Pharma Inc. (NASDAQ:LTRN) – Equities researchers at Zacks Small Cap upped their FY2024 earnings estimates for Lantern Pharma in a report released on Tuesday, November 12th. Zacks Small Cap analyst J. Vandermosten now expects that the company will earn ($1.90) per share for the year, up from their previous forecast of ($2.12). The consensus estimate for Lantern Pharma’s current full-year earnings is ($1.90) per share. Zacks Small Cap also issued estimates for Lantern Pharma’s Q4 2024 earnings at ($0.51) EPS and FY2025 earnings at ($1.86) EPS.

Lantern Pharma Trading Up 1.4 %

LTRN opened at $3.54 on Thursday. Lantern Pharma has a 12 month low of $3.04 and a 12 month high of $11.99. The business’s 50-day moving average price is $3.59 and its 200-day moving average price is $4.44. The company has a market cap of $38.18 million, a P/E ratio of -1.99 and a beta of 1.58.

Hedge Funds Weigh In On Lantern Pharma

A number of large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its stake in shares of Lantern Pharma by 24.5% during the second quarter. Renaissance Technologies LLC now owns 81,800 shares of the company’s stock valued at $382,000 after purchasing an additional 16,100 shares during the period. Dimensional Fund Advisors LP grew its holdings in Lantern Pharma by 55.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 18,413 shares of the company’s stock worth $86,000 after acquiring an additional 6,585 shares during the last quarter. CM Management LLC increased its position in shares of Lantern Pharma by 23.1% in the second quarter. CM Management LLC now owns 80,000 shares of the company’s stock valued at $374,000 after acquiring an additional 15,000 shares during the period. Westside Investment Management Inc. bought a new position in shares of Lantern Pharma during the second quarter valued at about $54,000. Finally, Tocqueville Asset Management L.P. purchased a new stake in shares of Lantern Pharma during the first quarter worth about $167,000. 28.62% of the stock is owned by hedge funds and other institutional investors.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.